Status:
COMPLETED
Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC)
Lead Sponsor:
Maastricht Radiation Oncology
Conditions:
Stage I-III Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The investigators' group was the first to perform a phase II trial in patients with limited disease (stage I-III) small-cell lung carcinoma (SCLC) in which only the fluorodeoxyglucose-positron emissio...
Detailed Description
Eligible patients (see below) will receive radiotherapy to the primary tumor and the initially involved mediastinal lymph nodes on FDG-PET scan to a dose of 45Gy in 30 fractions in 3 weeks (1.5Gy BID)...
Eligibility Criteria
Inclusion
- Histological of cytological proven SCLC
- UICC stage I-III, which are amendable for radical local treatment
- Performance status 0-2
- IMRT technique
Exclusion
- Not SCLC or mixed SCLC and other histologies (e.g. non-small cell carcinoma)
- Stage IV
- Performance status 3 or more
- No IMRT technique
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2017
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01166191
Start Date
May 1 2009
End Date
May 1 2017
Last Update
May 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MAASTRO clinic
Maastricht, Limburg, Netherlands, 6229 ET